An FDA advisory committee scheduled to deliberate on loosening restrictions around peptide compounding is facing criticism over the professional backgrounds of its newly appointed members, according to a report published by the BMJ.
The Committee and Its Mandate
The FDA's Pharmacy Compounding Advisory Committee comprises 12 voting members. The panel is set to convene over two days, on 23 and 24 July, to consider whether certain peptides should be added to the FDA's list of substances that licensed pharmacies and physicians are permitted to compound for individual patients.
Compounding, in regulatory terms, refers to the practice by which licensed pharmacies combine or otherwise alter drug ingredients to produce customised medications tailored to specific patients — preparations that are not available as standard off-the-shelf products. The FDA maintains a formal list governing which substances may be used in this process, though inclusion on that list does not constitute an agency endorsement of a substance's safety or effectiveness.
New Appointments Draw Scrutiny
FDA officials publicly disclosed the committee's revised composition on 29 June, revealing that at least eight of its members were newly appointed. It is among those new members that conflict-of-interest concerns have been concentrated.
According to the BMJ, critics have noted that seven of the newly added members have active health or wellness businesses with involvement in the supply of peptides — the very category of substances the committee is being asked to evaluate. That figure represents a substantial portion of the new intake, and observers have raised questions about whether such commercial entanglements are compatible with the impartial advisory role the committee is expected to perform.
The source article includes a partial quotation from an unnamed critic:
I'm not sure how these...
The remark, though truncated in the published source, reflects broader unease about the integrity of the appointment process.
Why Peptide Compounding Is Contested
Peptides — short chains of amino acids — have attracted significant commercial interest in recent years, with a range of products marketed for purposes including weight management, tissue repair, and hormonal support. Because many peptides are not approved as finished drug products, compounding pharmacies have occupied a grey area in their distribution, subject to the FDA's oversight of what substances may legally be compounded.
A decision by the advisory committee to recommend that certain peptides be added to the FDA's compounding list could substantially expand the legal pathways through which these substances reach patients. That regulatory outcome would carry direct commercial implications for businesses operating in the peptide supply chain — which is precisely why the reported backgrounds of several committee members have attracted attention.
Conflicts of Interest in Regulatory Advisory Bodies
The concern raised in the BMJ report is not without precedent in the broader landscape of FDA advisory panels. Regulatory bodies routinely grapple with the tension between appointing members who possess genuine subject-matter expertise — often developed through industry involvement — and ensuring that those members are free from financial incentives that could colour their recommendations.
FDA advisory committees are generally required to disclose conflicts of interest, and the agency has mechanisms for granting waivers in cases where a member's expertise is deemed to outweigh the risk posed by a financial relationship. However, critics argue that the scale of potential conflicts alleged in this instance — spanning seven of the new appointments — is unusual and warrants closer examination before the July meeting proceeds.
The BMJ's reporting does not detail whether formal conflict-of-interest disclosures were filed by the members in question, nor whether the FDA has indicated any intention to review the committee's composition ahead of the scheduled deliberations.
What Happens Next
The two-day meeting remains scheduled for late July. Advisory committee recommendations are not binding on the FDA, but they carry significant weight in shaping the agency's subsequent regulatory decisions. A recommendation in favour of expanding the compounding list for peptides could influence policy affecting both clinical practice and a commercially active market.
Whether the conflict-of-interest allegations reported by the BMJ prompt any formal response from the FDA — or lead to changes in the committee's membership or procedures — remains to be seen as the meeting date approaches.